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Introduction: Rheumatoid arthritis (RA) is characterized by decreased androgen levels, which was the first
hormonal abnormality described. Several studies indicated that steroidogenesis is directed towards endogenous
glucocorticoids at the expense of androgens. The decisive step governing androgen synthesis is the 17,20-lyase
activity of the CYP17A1 gene-encoded enzyme cytochrome P450 17A1. Here, we focused on the role in RA of the
critical cofactor for 17,20-lyase activity, cytochrome b5, encoded by the CYB5A gene.
Methods: Data sets of two genome wide RA association studies (GWAS) were screened for single nucleotide
polymorphisms (SNP) in the CYB5A gene. Candidate SNPs in CYB5A were studied in a case–control study population
of Slovakia. Expression analyses were done in synovial fibroblasts from RA patients by quantitative real-time polymerase
chain reaction, and cytochrome b5–expression was detected by immunohistochemistry. Real-life androgen production
after steroid conversion was measured using radiolabeled substrates.
Results: The study identified the RA-associated intronic SNP rs1790834 in the CYB5A gene in one GWAS and confirmed the
same SNP in our study. The minor allele reduced RA risk selectively in women (P = 4.1*10−3; OR = 0.63, 95% CI [0.46-0.86]).
The protective effect was confined to rheumatoid factor-positive (OR = 0.53, [0.37-0.75]) and anti-cyclic citrullinated
peptide-positive (OR = 0.58, [0.41-0.83]) cases, respectively. The protective allele doubles CYB5A mRNA-expression
resulting in 2-3fold activation of steroid 17,20-lyase activity, and protective allele was accompanied by a higher
density of cytochrome b5-positive cells in synovial tissue.
Conclusions: CYB5A is the first RA susceptibility gene involved in androgen synthesis. Our functional analysis of
SNP rs1790834 indicates that it contributes to the sex bias observed in RA.Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory joint
disease that affects about 0.5 to 1.0% of the population. It
causes increasing disability leading to a huge socioeco-
nomic burden [1]. In RA, risk variants in 46 loci explain
about half of the genetic risk, indicating that other so far
unknown loci are involved [2,3]. Despite the autoimmune
etiology, neuroendocrine immune pathways relevant for
inflammatory processes are discussed in RA onset and
progression [4]. In RA there is a clear preponderance of
affected women over men (3:1) [5]. This suggests that
high concentrations of estrogens, low concentrations of* Correspondence: rainer.straub@ukr.de
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stated.androgens, or a combination of both increase the risk
for RA [6].
Several androgens have anti-inflammatory properties.
Dehydroepiandrosterone (DHEA), androstenedione, and
testosterone inhibit secretion of IL-1β, IL-6, TNF, and
others [7-12]. The androgen 5α-dihydrotestosterone in-
hibits activation of the human IL-6 gene promoter stimu-
lated by nuclear factor kappa B [13], and it decreases T cell
proliferation [14]. There is evidence that some RA patients
of both sexes have reduced amounts of serum androgens,
even years before disease onset [15,16]. Particularly, female
RA patients have lower than normal levels of DHEA and/
or DHEA sulfate. In male RA patients, levels of serum tes-
tosterone are negatively correlated with disease severity
[15]. Two double-blind interventional studies with testos-
terone demonstrated some benefit in patients with RA
[17,18]. A preponderance of serum glucocorticoids over
serum androgens is known in many chronic inflammatoryhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Characteristics of the study sample for
association analyses
Variable Rheumatoid
arthritis cases
Rheumatoid arthritis-
free controls
(n = 521) (n = 321)
Sex, % female (n) 83.3 (434) 72.0 (231)*
Age at inclusion,
years (range)
51.6 ± 11.2 (19 to 80) 39.4 ± 15.1 (18 to 78)*
Age of onset, years
(range)
40.7 ± 12.8 (2 to 75) NA
Duration of disease,
years (range)
10.8 ± 8.3 (1 to 45) NA
Rheumatoid factor,
IU/mla
149.8 ± 67.2 ND
Rheumatoid factor-
positive, % (n)
55.0 (279) ND.
Anti-CCP antibody,
RU/mlb
67.5 ± 53.7 ND
Anti-CCP positive,
% (n)c
78.6 (239) ND
C-reactive protein,
mg/l
19.6 ± 23.7 ND
Values denote mean ± standard deviation unless indicated otherwise.
*Significant (P <0.001); arheumatoid factor serum levels were determined in
507 rheumatoid arthritis cases; banti-CCP antibody serum levels were
determined in n = 304 RA patients; cvalues <4.2 RU/ml were considered as
anti-CCP negative. NA, not applicable; ND, not determined; anti-CCP: antibody
against cyclic citrullinated peptide specific for rheumatoid arthritis.
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summary, there is convincing evidence that a relative lack
of androgens is involved in the etiology of RA.
However, we do not know molecular mechanisms re-
sponsible for this state of androgen deficiency. A recent
study revealed a negative correlation of serum testosterone
levels with RA disease activity in male patients under ther-
apy with disease-modifying anti-inflammatory drugs [20].
This indicates that the inflammatory disease can reduce
androgen levels. This may depend on increased androgen-
to-estrogen conversion that can happen in inflammatory
cells such as macrophages and osteoblasts [21-23]. In-
creased estrogen formation and estrogen-to-androgen ra-
tios were found in the synovial fluid of RA patients
compared to controls showing increased aromatase activ-
ity [24]. We demonstrated that mixed synoviocytes from
patients with RA and osteoarthritis convert DHEA, andro-
stenedione, and testosterone into downstream hormones
[25]. If androgens like testosterone are missing in the
tissue, synovial aromatase activity is strongly stimulated,
and this leads to a very high synovial estrogen-to-
testosterone ratio [6,25].
In addition, in collagen type-II arthritic animals and in
synovial fibroblasts from RA patients, conversion of
DHEA into the proinflammatory metabolite 7α hydroxy-
DHEA is increased (gene CYP7B1) [26,27]. This means
that DHEA is not available for conversion to androgens
such as androstenedione and testosterone.
However, these findings in patients with overt inflam-
matory disease do not explain why androgen levels are
lower than normal before disease outbreak [15,16]. Some
authors speculated that male RA patients without gluco-
corticoid treatment might be in a state of (compensated)
partial gonadal failure [28]. However, molecular path-
ways of adrenal or gonadal failure are not known, and
this was subject of our study.
Endogenous de novo synthesis of androgens depends
on two key enzyme activities, 17α-hydroxylase and
17,20-lyase, both linked to one protein encoded by the
cytochrome P450 17A1 gene CYP17A1 [29]. While 17α-
hydroxylase activity is essential for synthesis of androgens
and cortisol depending on the presence of NADPH-
cytochrome P450 reductase (POR) [29], the 17,20-lyase
activity depends on the combined presence of POR and
the cofactor cytochrome b5 type A (gene on chromosome
18, CYB5A) [29,30].
In order to study molecular pathways relevant to andro-
gen deficiency, we focused on cytochrome P450 17A1 and
cytochrome b5 type A. In the two published RA genome-
wide association study (GWAS) datasets, we reanalyzed
single nucleotide polymorphisms (SNP) in the CYB5A
gene [31,32]. In a novel RA case-control study with Slovak
people, we investigated the same SNPs in the CYB5A
gene. Then, we functionally analyzed SNP alleles bysteroidogenic gene expression and pregnenolone con-
version into androgens in synovial fibroblasts of RA pa-
tients. In addition, density of cytochrome b5A-positive
synovial cells was investigated in RA synovial tissue.Methods
Study sample
A total of 842 (117 male, 665 female) Slovak individuals
were included for genotyping, with 521 (87 male, 434 fe-
male) RA patients and 321 (90 male, 231 female) healthy
controls without any arthritic symptoms. Rheumatoid
factor (RF) was determined by standard techniques. Meas-
urement of antibody against cyclic citrullinated peptide
(anti-CCP) was carried out using an anti-CCP ELISA
(Euroimmun, Lübeck, Germany) following the manufac-
turer’s instructions. From a total of 304 RA patients anti-
CCP levels were determined. Values <4.2 RU/ml were
anti-CCP negative. The characteristics of these patients
are given in Table 1.
Synovial fibroblasts were isolated from 40 patients
with longstanding RA fulfilling the American College of
Rheumatology (formerly, the American Rheumatism
Association) revised criteria for RA [33]. These patients
underwent elective knee joint replacement surgery. We
obtained written consent of patients according to the
current Declaration of Helsinki. The study was approved by
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atic Diseases, Piestany, Slovakia, and the Ethics Committee
of the University of Regensburg, Germany.
Marker selection and genetic analyses in case-control study
SNPs in CYB5A genomic region (NM_148923.3) with
10 kb on the 5′ and 3′ end, respectively (chromosome
18: 71,910,527-71,969,251; NCBI build 37.3), were se-
lected based on published information from two GWAS
on RA with P <0.01 (see Table 2, and previous publica-
tions [31,32]).
Genomic DNA was isolated from whole blood samples
using the PureGene DNA Blood Kit (QIAGEN, Hilden,
Germany). DNA samples were genotyped using 5′ exo-
nuclease TaqMan® technology (Life Technologies, Ap-
plied Biosystems, Foster City, CA, USA) following the
manufacturer’s instructions. In brief, for each genotyp-
ing experiment 10 ng DNA was used in a total volume
of 5 μl containing 1 × TaqMan® Genotyping Master Mix
(Applied Biosystems). Real-time polymerase chain reac-
tion (RT-PCR) and post-RT-PCR endpoint plate read
was carried out according to the manufacturer’s instruc-
tions using the Applied Biosystems 7900HT RT-PCR
System. Sequence Detection System software version 2.4.1
(Applied Biosystems) was used to assign genotypes apply-
ing the allelic discrimination test. Case and control DNA
were genotyped together on the same plates with dupli-
cates of samples (10%) to assess intraplate and interplate
genotype quality. No genotyping discrepancies were de-
tected. Assignment of genotypes was performed by a per-
son without knowledge of sample case-control status.
Preparation of synovial tissue and culture of synovial
fibroblasts
Synovial tissue samples from patients with RA were ob-
tained immediately after opening the knee joint capsule as
previously described [34]. Pieces of synovial tissue of up to
9 cm2 were excised. One part of the tissue sample was cut,
paraffin-embedded, and stored until further use (immuno-
histochemistry, see below). Another part of the synovial
tissue specimen was minced and put in Dispase I (Roche
Diagnostics, Mannheim, Germany). Digestion lasted for at
least 1 hour at 37°C on a shaking platform. The resulting
suspension was filtered (70 μm filter) and spun at 300 g
for 10 minutes. We treated the pellet with erythrocyte lysis
buffer (20.7 gm NH4Cl, 1.97 gm NH4HCO3, 0.09 gm
EDTA, and 1 liter of H2O) for 5 minutes followed byTable 2 CYB5A single nucleotide polymorphism (SNP) marker
SNP Position on
chromosome 18a
Localizationb Major
allele (1)
M
al
rs1790858 71924819 Intron 3 C T
rs1790834 71948257 Intron 1 G A
aNCBI build 37.3; brelative to NM_148923.3; cprevious publication [32]; dprevious pucentrifugation for 10 minutes at 300 g. The pellet was re-
suspended in RPMI 1640 (Sigma-Aldrich, St Louis, MO,
USA) with 10% fetal calf serum. We transferred 1,000,000
cells to a 75-cm2 tissue culture flask, incubated them over-
night, and supplemented these cells with fresh medium.
Synovial fibroblasts derived from these cultures were
routinely used in passages two or three, where these cells
are known to conserve their phenotype [35]. Cells were
seeded into 6-well plates for steroid conversion experi-
ments or 25-cm2 tissue culture flasks for nucleic acid iso-
lation and were kept in a humidified atmosphere with 5%
CO2 at a temperature of 37°C.
Nucleic acid extraction and quantitative RT-PCR analysis
Synovial fibroblasts were disrupted using QIAshredder
colums (QIAGEN). Total cellular RNA and DNA were
isolated in parallel from cultured cells using the All-
Prep DNA/RNA Mini Kit (QIAGEN). Genotyping was
done as described above and cDNAs were generated
from RNA by reverse transcriptase reaction using Affi-
nityScript quantitative RT-PCR synthesis kit (Agilent
Technologies, Böblingen, Germany). RT-PCR was per-
formed using TaqMan primer/probes (Applied Biosys-
tems - Life Technologies, Darmstadt, Germany) targeting
two isoforms of CYB5A gene (Hs00157217_m1 and
Hs01076969_m1). In addition, expression of several
genes coding for enzymes relevant for steroid metabol-
ism was assessed in synovial fibroblasts using TaqMan
assays: 17α-hydroxylase/17,20-lyase (Hs01124136_m1
for CYP17A1), NADPH-cytochrome P450 reductase
(Hs01016332_m1 for POR), 3β-hydroxysteroid dehydro-
genase isoforms (Hs00426435_m1 for HSD3B1, Hs00
605123_m1 for HSD3B2, and Hs00228639_m1 for
HSD3B7, respectively), the 25-hydroxycholesterol 7α-
hydroxylase cytochrome P450 7B1 (Hs00191385_m1for
CYP7B1), and aromatase cytochrome P450 19A1 (Hs00
903413_m1 for CYP19A1). Relative gene expression was
normalized to HPRT1 mRNA (Hs01003267_m1) levels
using the comparative cycle threshold (Ct) method and
presented as expression ratio using 2-ΔΔCt [36]. RA
cDNA with ΔCt value next to the median of the ΔCt
distribution was used as calibrator sample.
Immunocytochemistry
Human cytochrome b5 type A was detected and quan-
tified using immunohistochemistry. Five-micrometer
sections were cut from paraffin-embedded blocks. Forused in analysis
inor
lele (2)
P (odds ratio)
in GWAS
TaqMan assay Call rate in 842
samples
0.0095 (0.44)c C___7536288_10 1
0.0073 (0.83)d C___7536393_20 0.962
blication [31]. GWAS, genome-wide association studies.
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xylol and ethanol and rehydrated in a descending etha-
nol series. The slides were placed in a 0.1 mol/L citrate
buffer (pH = 6.0) and boiled for 20 minutes at 120°C.
Slides were then washed in PBS buffer (pH = 7.6), and
treated briefly with 2% hydrogen peroxide in 1 × PBS
for 10 minutes to block endogenous peroxidase activity.
Slides were incubated for 45 minutes in blocking solution
consisting of 10% bovine serum albumin (PAA, Inc.,
Pasching, Austria), 10% fetal calf serum (PAA, Inc.), and
10% goat serum (Sigma, Steinheim, Germany). After
blocking, sections were incubated with primary antibody
(1:500, ab69801, Abcam, Cambridge, MA) overnight at
room temperature. After incubation with biotinylated
secondary antibody (1:200, polyclonal goat anti-rabbit IgG
biotinylated, from Dako, Hamburg, Germany) for 90 mi-
nutes, the sections were treated with streptavidin-
horseradish peroxidase (GE Healthcare Europe GmbH,
Munich, Germany). Visualization was performed with
diaminobenzidine tetrahydrochloride hydrate (ImmPACT
DAB substrate, Vector Laboratories, Peterborough, UK).
Staining with control serum always yielded negative re-
sults, and liver tissue was used as positive control. In order
to determine the tissue density of cytochrome b5-positive
cells, the number of positive cells was averaged from 17
randomly selected high-power fields (400×). The number
of investigated high-power fields was derived from a pio-
neering histological study [37].
Incubation with radiolabeled steroids and steroid extraction
For steroid conversion experiments synovial fibroblasts
in 6-well plates were washed with PBS and incubated
with RPMI 1640 (without phenol red or serum, but sup-
plemented with 15 mM HEPES, 2 mM stable glutamine
and 40 mg/l gentamycin) (PAN Biotech, Aidenbach,
Germany). After 3 hours, the radiolabeled substrate
7-3H(N)-pregnenolone (Preg, 5-pregnen-3β-ol-20-one)
(PerkinElmer, Rodgau-Jügesheim, Germany) was added
for another 24 hours at a final concentration of 25 nM
containing an activity of 37,000 Bq.
The fibroblast monolayers were fixed overnight with
10% formaldehyde, washed with saline, and nuclei were
stained with Hoechst 33258. Large-area images were
taken on a Cell Observer microscopic system (Carl Zeiss,
Jena, Germany) and counted nuclei were taken as cell
numbers for normalization of steroid conversion results.
From the cell-free supernatants steroids were ex-
tracted twice with 3 ml cold ethyl acetate. The exact
concentration of radiolabeled steroid applied to every
well and the extraction efficiencies were monitored by
liquid scintillation counting of aliquots in Ultima Gold
cocktail (PerkinElmer): recoveries of radioactivity in the
organic phase varied insignificantly (97.2 ± 1.5%, mean ±
SD). The stable extracts were lyophilized in a speed-vacconcentrator (Saur, Reutlingen, Germany) and stored
at −20°C until analysis.
Two-dimensional thin-layer chromatography (2D-TLC)
of steroids
Pregnenolone and its metabolites with respect to andro-
gen synthesis [29] (Figure 1A) were separated essentially
as described previously [22], with modifications as given
below. Solvents and other reagents were purchased from
Merck (Darmstadt, Germany), if not stated otherwise.
Unlabeled steroids were from Sigma (Steinheim, Germany)
and from Steraloids (Newport, RI, USA). Stock solutions
were prepared in ethanol. Lyophilized steroid extracts were
dissolved in 50 μl ethanol, spotted under a nitrogen stream
with a Linomat IV (Camag, Muttenz, Switzerland) on silica
gel 60 F254 TLC aluminum sheets (Merck) together with a
mixture of unlabeled carrier steroids (Figure 1B). The
first separation of 2D-TLC was done in toluene:metha-
nol (90:10). The second dimension of the separation
was done by two successive developments in chloro-
form:diethylether (90:10). For identification of spots, the
2D-TLC plates were stained with copper acetate in
phosphoric acid as described previously [22]. Radioactivity
on the 2D-TLC plates was quantified by radioimaging on
an FLA 3000 (Fuji-Raytest, Straubenhardt, Germany).
Spots were assigned only if their intensity was more than
two standard deviations above background. Spot inten-
sities were corrected for corresponding values obtained
from blank wells incubated with radiolabeled pregneno-
lone without cells. The results were calculated as pmol
of steroid produced per million cells in a 24-hour incu-
bation period.
Statistical and bioinformatical analyses
Differences between dichotomous traits were calculated
employing the chi-square (χ2) test. Differences in con-
tinuous variables between groups were calculated using
the two-tailed t-test for normally distributed data or the
non-parametric Mann-Whitney U-test for variables not
normally distributed as determined by the Shapiro-Wilk
test. Expression data were compared between the three
genotypes after grouping the minor allele carriers (dom-
inant model). Logistic regression was used for the differ-
ent models in association analyses (sex as a covariate,
stratified by sex, and stratified by either RF or anti-CCP
status). Odds ratios (OR) and 95% CI were calculated.
To determine whether the genotypes of cases and controls
of all SNPs deviated from Hardy-Weinberg equilibrium,
actual and predicted genotype counts of both groups were
compared by the exact test [38]. A P-value <0.05 was con-
sidered significant.
Association analyses were performed with PLINK v1.07
[39]. Statistical software packages JMP 7.0.2 (SAS Institute
Inc, Cary, NC, USA) and SigmaPlot 11.2.05 Systat Software
Figure 1 Analysis of pregnenolone metabolism in rheumatoid
arthritis synovial fibroblasts. (A) Pathways and enzymes of
pregnenolone metabolism as identified in synovial fibroblasts
(reviewed in a previous publication [29]). (B, D) Two-dimensional
thin layer chromatography (2D-TLC) separation of pregnenolone
and its metabolites. (B) Position of unlabeled steroid standards
of identified metabolites (circles) overlaid to the 3H-image of the
pregnenolone substrate used. (C) 3H-image from a GG-fibroblast line
accumulating (besides compound X) 17α-hydroxy-pregnenolone, the
direct product 17α-hydroxylase activity, together with 7α-hydroxy-
dehydroepiandrosterone (DHEA). (D) 3H-image from an AG-fibroblast
line accumulating almost exclusively 7α-hydroxy-DHEA. CYB5A,
cytochrome b5, type A; CYP17A1, steroid 17α-hydroxylase/17,20-lyase
(cytochrome P450 17A1). E2 was found in a minority of fibroblasts only.
*Start indicates point of sample application. X indicates the major
product formed from pregnenolone by fibroblasts independently
from rs1790834 genotype. Arrows indicate the metabolites with
production dependent on the rs1790834 genotype. CYP7B1, 25-
hydroxycholesterol 7α-hydroxylase (cytochrome P450 7B1); HSD3B,
3β-hydroxysteroid dehydrogenase; Δ5Adiol, Δ5-androstenediol;
Adione, androstenedione; Preg, pregnenolone; Prog, progesterone;
Testo, testosterone. E2, estradiol.
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Meta-analysis weighted according to sample size was
performed using METAL with Cochran’s Q-test for het-
erogeneity [40,41]. For linkage disequilibrium testing,
HaploView v4.2 was employed [42] with HapMap ver-
sion 3 data from release 28 [43]. A power calculation
was performed with Quanto 1.2.4 (Division of Biostatis-
trics, USC University of Southern California, Los Angeles,
CA, USA) assuming a population risk of 1% for RA.
MatInspector v8.05 and SNPInspector 2.2 (Genomatix
Software GmbH, Munich, Germany) were used to analyze
the potential functional consequences of SNPs on tran-
scription factor binding sites.
Gene expression and steroid conversion data are shown
as mean ± SD, if all data in a figure were normally distrib-
uted. Otherwise, data are presented as box plots, where
boxes represent the 25th and 75th percentiles, respect-
ively. The median is indicated by a horizontal line. The
whiskers indicate the 10th and 90th percentiles, respect-
ively. Dots represent individual outliers.
Results
Genotyping and association study
Two recently published GWAS on RA susceptibility
[31,32] were screened for association between disease
and CYB5A polymorphisms, resulting in two SNPs with
P <0.01. In our Slovak RA case-control sample (Table 1),
we sought direct replication of these SNPs (Table 2). In
our sample, controls were significantly younger than
cases at inclusion into the study but were in a compar-
able age range when the onset of disease in RA cases
was compared to age at inclusion of controls. Signifi-
cantly more females were present in the case group.
Both markers fulfilled our criteria of at least a 95% call
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was observed (Table 3). Allele frequencies for the two
SNPs were consistent between HapMap release 28 data
for the population of Utah residents with ancestry from
northern and western Europe (called the CEU popula-
tion) and our disease-free controls (1% and 18% in Hap-
Map and 1.2% and 18.9% in controls for rs1790858 and
rs1790834, respectively).
After adjustment for sex, rs1790834 showed association
with risk of RA (P = 8.5*10−3; OR = 0.69, 95% CI 0.52,
0.91) (Table 3). Additional adjustment for age (age at in-
clusion for controls and age of onset for RA patients) did
not change the association results (data not shown).
Meta-analysis with the initial association data from a pre-
vious publication [31] resulted in P = 3.6*10−4 (OR = 0.76,
95% CI 0.69, 0.84), that is, a protective effect of the minor
allele. No heterogeneity was detected (P = 0.237).
When the association of rs1790834 with risk of RA
was analyzed separately for both sexes, there was signifi-
cant association only for women with P = 4.1*10−3; OR =
0.63 (95% CI 0.46, 0.86; n = 434 cases, n = 231 controls).
There was no association detectable for men (n = 87 cases,
n = 90 controls) in our study sample (P = 0.81; OR = 0.93,
95% CI 0.52, 1.67).
In addition, stratified analysis for RF-positive (n = 279)
and RF-negative cases (n = 228) was performed: rs1790834
showed only significant association results in RF-positive
cases with P = 3.3*10−4 (OR = 0.53, 95% CI 0.37, 0.75) in
contrast to RF-negative cases with P = 0.38 (OR = 0.86,
95% CI 0.62, 1.20). In addition, in the anti-CCP positive
subset of RA patients, significant association between
rs1790834 and the disease was detected with P = 2.7*10−3
(OR = 0.58, 95% CI 0.41, 0.83).
Gene expression analysis
Synovial fibroblast RNA samples from 22 RA patients
with measured rs1790834 genotypes were available for
gene expression analysis. SNP rs1790834 is located in the
first intron of the CYB5A gene, that is, not within the pro-
tein coding sequence. Therefore, we first verified expres-
sion of CYB5A and several key genes of pregnenolone
metabolism: fibroblasts expressed the longest mRNA-
transcript of CYB5A (GenBank NM_148923; cytochrome
b5 isoform 1), which encodes the membrane-bound fully
functional cytochrome b5. In addition, CYP17A1 andTable 3 CYB5A single nucleotide polymorphism (SNP) associa
control replication sample of Slovak patients and controls
RA case genotypes RA-free co
SNP 11 12 22 MAF P (HWE) 11 12
rs1790858 510 11 0 0.011 1 313 8
rs1790834 388 122 11 0.138 0.71 187 95
aLogistic regression adjusted for sex. Numbers of genotypes according to alleles froPOR as prerequisite for DHEA synthesis (and hence an-
drogen synthesis), and HSD3B2, HSD3B7, CYP7B1 and
CYP19A1 as prerequisite for downstream processing of
DHEA were expressed in synovial fibroblasts (Figure 2A),
whereas HSD3B1 was not found.
In a second step, we tested whether the minor
rs1790834 A-allele has an effect on gene expression levels.
Comparing CYB5A mRNA expression levels, the mean
expression of CYB5A was significantly higher within car-
riers of the minor allele (Figure 2B). The rs1790834 geno-
type had no effect on the expression levels of the other
steroidogenic genes expressed in synovial fibroblasts
(Figure 2B), indicating that the SNP specifically affects
CYB5A expression.
Biobank tissue sections were available for a subgroup
of RA patients. In these tissue sections, we studied immu-
nohistochemically investigated density of cytochrome b5-
positive cells. Density of positive cells positively correlated
with amount of mRNA (n = 8, r2 = 0.64, P = 0.017; data
not shown). Thus, the minor rs1790834 A-allele facilitates
higher cellular cytochrome b5 contents.CYB5A genotype affects pregnenolone metabolism in RA
synovial fibroblasts
As fibroblasts metabolize various steroid substrates, we
tested whether the CYB5A genotype affects the conver-
sion of pregnenolone into downstream metabolites. This
pathway was studied because the key enzyme for andro-
gen synthesis, the 17,20-lyase activity of cytochrome P450
17A1, depends on cytochrome b5, the product of the
CYB5A gene.
Synovial fibroblasts from 40 genotyped RA patients
(n = 27 for major allele GG carriers, n = 13 for minor al-
lele AA/AG carriers) converted radiolabeled pregneno-
lone into a variety of steroids (for products/pathways
identified see Figure 1A). By 2D-TLC we identified nine
products of pregnenolone metabolism (Figure 1B-D).
There were no allele-dependent differences in the produc-
tion of progesterone, 17α-hydroxyprogesterone, DHEA,
androstenedione, androstenediol, testosterone, and an un-
identified product X, which was the major product from
fibroblasts, but independent of genotype (GG: 187 ± 152
versus AA/AG: 233 ± 175 pmol/(106 cells*24 hours),
mean ± SD; t-test: P = 0.40) (Figure 3A, B).tion analysis results in a rheumatoid arthritis (RA) case-
ntrol genotypes Association results
22 MAF P (HWE) Pa Odds ratio for minor
allele (95% CI)a
0 0.012 1 0.835 0.91 (0.36, 2.30)
7 0.189 0.25 8.5*10−3 0.69 (0.52, -0.91)
m Table 2. MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium.
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Figure 2 Effect of rs1790834 genotypes on expression of CYB5A and steroidogenic genes. Real-time quantitative PCR analysis of mRNA
expression in 22 RA synovial fibroblast lines (rs1790834 genotype GG, n = 15; AA/AG genotypes, n = 7). (A) Synovial fibroblasts express all genes,
which are necessary for synthesis of biologically active androgens. Mean ± SD of expression levels normalized to HPRT1 of combined data for all
genotypes. (B) rs1790834 genotype-dependent expression levels, which are normalized to the median value of the combined expression data for
each gene. In the box-and-whisker plots the genotypes with the rare allele A were grouped together (AA, n = 1; AG, n = 6). The boxes represent
the 25th to 75th percentiles, and horizontal lines within the box represent median values. The whiskers show the 10th and 90th percentiles,
respectively, and dots represent individual values exceeding these limits. ***Significant rs1790834 genotype-dependent expression, P <0.005,
Mann-Whitney rank-sum test. CYB5A, cytochrome b5, type A; CYP17A1, steroid 17α-hydroxylase/17,20-lyase (cytochrome P450 17A1); CYP19A1,
aromatase (cytochrome P450 19A1); CYP7B1, 25-hydroxycholesterol 7α-hydroxylase (cytochrome P450 7B1); HPRT1, hypoxanthine(−guanine)
phosphoribosyltransferase 1; HSD3B2/7, 3β-hydroxysteroid dehydrogenase isoforms 2/7; POR, NADPH-cytochrome P450 reductase.
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hydroxylase activity, 17α-hydroxy-pregnenolone, in syn-
ovial fibroblasts from carriers of the minor A-allele was
significantly lower than in non-carriers (GG-genotype)
(Figure 3A). Carriers of the minor A-allele produced
roughly 2.5 times the amount of 7α-hydroxy-DHEA
than non-carriers (P = 0.009, Figure 3B). As production
of 7α-hydroxy-DHEA depends on DHEA availability
this metabolite indicates increased 17α-hydroxylase and
17,20-lyase activity.
Decreased ratios of 17α-hydroxylase over 17,20-lyase
activity would be expected when the CYB5A A-allele
stimulates the latter enzyme step via increased availabil-
ity of cytochrome b5. Therefore, metabolite ratios wereA B
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progesterone)/17,20-lyase, were significantly decreased
(P = 0.006, P = 0.022, and P = 0.03, respectively) in syn-
ovial fibroblasts from RA patients with the rs1790834
A-allele (Figure 3C-E), clearly indicating an effect of the
CYB5A genotype on steroid 17,20-lyase activity.
Finally, the two groups of the study were compared in
order to check homogeneity with respect to clinical
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(G) (age 63 versus 68 years; female/male 83%/17% versus
90%/10%; and dosage mean ± standard error of the mean
4.58 ± 1.00 versus 6.50 ± 1.50 mg/day). Similarly, the fre-
quency of prednisolone and methotrexate treatment was
similar in the two groups (prednisolone 83% versus 80%,
and methotrexate 33% versus 10%). The patients did not
receive anti-TNF therapy or other disease-modifying
anti-inflammatory drugs because the disease was in a
mild and late stage. In addition, markers of inflamma-
tion like C-reactive protein (23.4 ± 14.8 versus 16.8 ±
4.1 mg/l) and erythrocyte sedimentation rate (21 ± 5
versus 39 ± 17 mm/1st hour) were not significantly dif-
ferent between groups.
Discussion
Owing to the design of GWAS, below their threshold of
unambiguous detection important genetic variants re-
main hidden (in a so-called sea of noise). Nevertheless,
these genetic variants may contribute significantly to the
risk of RA. Instead of enforcing more statistical power
by increasing numbers of cases and controls in GWAS,
a hypothesis-driven approach combined with functional
analyses can help to unravel significant contributions of
candidate genes to risk of RA [44]. RA is associated with
comparatively low androgen levels, both systemically and
within the inflamed tissue [20,24,25,45,46]. Therefore, we
screened the data sets of two published GWAS for poly-
morphisms in the CYB5A gene [31,32], which is relevant
for steroid metabolism and identified two RA-associated
SNPs linked to low androgen secretion.
In our Slovak case-control study sample, the minor al-
lele of SNP rs1790834 was associated with reduced risk
for RA. The power for this replication of a GWAS finding
[31] was about 42% in our study with 521 cases and 321
controls (using the reported OR = 0.83, minor allele fre-
quency = 18% and one-sided P-value = 0.05). In subgroup
analysis, we detected association between SNP rs1790834
in RF-positive RA cases only. This is consistent with the
initial study by Plenge et al., including patients that were
seropositive for anti-CCP [31]. Anti-CCP is a better diag-
nostic marker than RF, and the correlation between the
two factors is moderate [47]. Although anti-CCP levels
were only available in a subset of our RA patients, we
again found a strong association between rs1790834 and
the disease in this subgroup. Altogether, our data and the
initial data by Plenge et al. [31] suggest that rs1790834-
driven association with RA is limited to an RF/anti-CCP-
positive disease entity. Heritability is in a similar range for
both anti-CCP-positive and -negative RA, but these repre-
sent different disease entities [48].
Importantly, stratification for sex revealed an associ-
ation between rs1790834 and RA only in women in our
study, indicating a strong sex bias for the protectiveeffect of the minor allele A. One possible explanation is
the reduced power in our male sample with 87 cases
and 90 controls (36% power given an OR of 0.69, an al-
lele frequency of 18.9% in controls, a nominal signifi-
cance with one-sided P-value = 0.05 in an additive model
and an assumed population risk of 1%). In comparison,
the power was 77% to detect this effect in women (434
cases and 231 controls). However, as RA is a disease with
higher prevalence in women than in men, sexual hor-
mones are thought to possibly be involved in disease onset
and progression [4].
With a minor allele frequency of about 18% for
rs1790834 this CYB5A polymorphism is not rare. Add-
itional SNPs may even increase the contribution of
CYB5A polymorphisms to reduction of RA risk. Our
inability to replicate the effect of the other SNP,
rs1790858 [32], does not contradict this notion because
the protective allele frequency of 1% for this SNP is too
low to be detected by our study design. In contrast, it
suggests that in future work all independent SNPs in
the CYB5A gene should be analyzed in detail for their
possible contribution to RA risk.
Cytochrome b5, the protein encoded by the CYB5A
gene, has diverse functions, which are of varying import-
ance in different tissues and cell types. Notably, NADH-
dependent reduction of methemoglobin (erythrocytes),
electron transfer to fatty-acid desaturases (mainly liver),
and steroid and xenobiotics metabolism by cytochrome
P450 enzymes depend on cytochrome b5 [29,49,50]. Cyto-
chrome P enzyme activity is increased by at least two
different mechanisms: either cytochrome b5 mediates
electron transport to cytochrome P450 enzymes or it facil-
itates allosteric interaction of selected cytochrome P450
enzymes with the electron donating NADPH-cytochrome
P450 reductase [49,50]. The latter mechanism potentiates
the activity of the affected cytochrome P450 enzymes,
amongst them enzymes involved in metabolism of xenobi-
otics [49], and the key enzyme activity for androgen bio-
synthesis, cytochrome P450 17A1 steroid 17,20-lyase, our
target enzyme [30]. As androgens and androgen metab-
olism play a role in the etiology of RA, there was an ob-
vious need to further analyze the SNP rs1790834 in this
context.
To test for functional consequences of CYB5A poly-
morphisms, a patient-specific source of tissue or cells
was indispensable. With respect to androgen synthesis,
this would be adrenal glands or gonads [29,51], which
are unavailable for these experimental studies in RA.
On the other hand, synovial fibroblasts are a validated
model for gene expression and functional studies in RA
research. They maintain a well-conserved phenotype in
cell culture over several passages [35,52], and patient-
derived fibroblast lines largely maintain their gene ex-
pression profiles [35].
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nenolone converting enzymes in synovial fibroblasts. As
expected for a cell type that is not primarily involved in
androgen production, the activities of those enzymes are
low when compared to activities in adrenals or gonads
[29,30,51]. Nevertheless, we found all enzymes necessary
for and all metabolites indicative of androgen biosynthesis
in synovial fibroblasts. Moreover, the critical step of an-
drogen synthesis, the 17,20-lyase activity of CYP17A1-
encoded cytochrome P450 17A1, clearly depends on the
CYB5A alleles (determining the amount of cytochrome
b5). High levels of cytochrome b5 can increase androgen
synthesis more than 10-fold in experiments using purified
enzymes from adrenals or gonads, respectively, or using
recombinant enzymes [30,53]. We found a 2- to 3-fold in-
crease of the capacity for androgen synthesis in synovial fi-
broblasts harboring the RA-protective allele A of SNP
rs1790834, which parallels the increase in CYB5A expres-
sion. This effect size is reasonable, as (1) almost all tested
fibroblast lines were from heterozygous donors (AG) and
(2) the major allele homozygous carriers (GG) express
CYB5A (at normal levels). Neither the expression levels of
CYP17A1 nor that of any other gene analyzed were al-
tered. Therefore, the intronic SNP, which does not alter
the protein sequence of the CYB5A-encoded cytochrome
b5, most likely exerts its effect specifically via control of
the expression level.
It should be emphasized that the accumulation of
(proinflammatory) 7α-hydroxy-DHEA is a specific fea-
ture of synovial fibroblasts, which express high levels of
CYP7B1-encoded cytochrome P450 7B1 [26,27], but not
a consequence of cytochrome b5 levels in general. For
tissues or cell populations, where cytochrome P450 7B1
is not the dominant enzyme for DHEA metabolism, the
CYB5A SNP would modulate the production of other
androgens and their metabolites.
Although adrenals and gonads from RA patients or
healthy controls are not amenable to direct testing, our re-
sults implicate that the identified CYB5A SNP may be gen-
erally responsible for facilitated androgen production in
these tissues of minor allele carriers. Correspondingly, the
major allele determines lower androgen levels [54], which
precede disease onset in RA patients [15,16]. In addition,
local androgen production in the inflamed joints would be
hampered by the major allele after disease onset [20,24,25].
In summary, the identified CYB5A SNP should affect
the 17,20-lyase step of androgen biosynthesis in all
tissues expressing cytochrome P450 17A1. Due to the
modulatory role of cytochrome b5 on 17,20-lyase activ-
ity, as outlined above, the alterations in pregnenolone
metabolism resulting from the possible SNP variant com-
binations are expected to be moderate. They should cause
less dramatic changes of the androgen (and downstream
metabolite) concentrations, than found, for example, inhuman isolated 17,20-lyase deficiency [55] or in the cyto-
chrome b5 knockout mouse [56], where androgens are
massively depleted. Nevertheless, the CYB5A SNP surely
contributes to the variance in androgen levels in the
population, which will be inconspicuous in the majority
of individuals. However, if activities of other enzymes
involved in steroid metabolism are low, the rs1790834
(GG) carriers are more likely than carriers of the A al-
lele to present signs of partial gonadal or adrenal failure
[20,28,29,51,57,58]. This was suggested to be involved in
the etiology of RA [15,16].
Conclusions
The CYB5A SNP contributes to the heritable risk in RA
women. It can be an important factor contributing to
the sex bias in RA incidence. As androgen levels in women
are generally lower than in men, any additional decrease
will disproportionately reduce the anti-inflammatory im-
pact of androgens. In other words, the risk-lowering minor
allele of SNP rs1790834 may help to ensure protective an-
drogen levels in women, whereas the major allele may con-
tribute to low androgen levels, which are insufficient to
block development of RA or to ameliorate the inflamma-
tory processes. In this setting the CYB5A SNP rs1790834 is
rather unimportant in men, which is reflected by the lack
of a protective role of the risk-lowering minor allele of
SNP rs1790834 in the male subgroup. A clinical implica-
tion of our results lies in the fact that any kind of androgen
therapy can be successful preferentially in CYB5A SNP
rs1790834 major allele carriers.
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